['psoriasis']
['bms-986165', 'placebo for bms-986165']

        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Male and female, ages 18 to 70 years

          -  Diagnosis of plaque psoriasis for 6 months

          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
             test, must not be pregnant, lactating, breastfeeding or planning pregnancy

          -  Males who are sexually active with WOCBP must agree to follow instructions for
             method(s) of contraception for the duration of treatment plus 5 half-lives of the
             study drug plus 90 days.

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  Blood transfusion within 4 weeks of study drug administration

          -  Inability to tolerate oral medication

          -  Positive hepatitis-B (HBV) surface antigen

          -  Positive hepatitis-C (HCV) antibody

          -  Any history or risk for tuberculosis (TB)

          -  Any major illness/condition or evidence of an unstable clinical condition

          -  Chest X-ray findings suspicious of infection at screening

          -  has received ustekinumab, secukinumab or ixekizumab within 6 months of first
             administration of study medication

          -  Has received anti-Tumor Necrosis Factor (TNF) inhibitor(s) within 2 months of first
             administration of study medication

          -  Has received Rituximab within 6 months of first administration of study medication

          -  Topical medications/treatments for psoriasis within 2 weeks of the first
             administration of any study medication

          -  Any systemic medications/treatments for psoriasis within 4 weeks of the first
             administration of any study medication

        Other protocol defined inclusion/exclusion criteria could apply
      